Compare GEN & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEN | DVA |
|---|---|---|
| Founded | 1982 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 14.9B |
| IPO Year | 1995 | 2003 |
| Metric | GEN | DVA |
|---|---|---|
| Price | $28.99 | $184.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | $32.88 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 5.5M | 597.0K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 52.43 | N/A |
| EPS | 0.36 | ★ 6.86 |
| Revenue | $6,676,000,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $27.40 | $3.85 |
| Revenue Next Year | $5.41 | $3.07 |
| P/E Ratio | $83.92 | ★ $26.69 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $17.78 | $101.00 |
| 52 Week High | $31.65 | $247.49 |
| Indicator | GEN | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 46.70 |
| Support Level | $25.26 | $173.99 |
| Resistance Level | $29.87 | $202.63 |
| Average True Range (ATR) | 0.77 | 5.37 |
| MACD | -0.20 | 2.04 |
| Stochastic Oscillator | 2.38 | 43.00 |
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.